Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epcoritamab · 1 trial · 1 indication
The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR at any moment since initiation. The CRR will be assessed by PET-CT according to Lugano Classification and is defined as the proportion of patients who achieve a best response of complete response (CR) at any moment since initiation of Epcoritamab first administration.
| Arm | Type | Description |
|---|---|---|
| EPCO monotherapy | EXPERIMENTAL | Epcoritamab in monotherapy will be administred until cycle 12. |
| Combination therapy | EXPERIMENTAL | 3 cycles of Epcoritamab in monotherapy will be administred and then Epcoritamab will be administred with Tafasitamab and Lenalidomide from cycle 4 until cycle 15. |
| Name | Type | Description |
|---|---|---|
| Epcoritamab | DRUG | Patients will receive 12 cycles of Epcoritamab monotherapy. |
| Epcoritamab, tafasitamab and lenalidomide | DRUG | Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide. |
Inclusion Criteria: 1. Written informed consent must be obtained before any study-specific assessment is performed. 2. Age \>18 years 3. Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell Lymphoma (PMBCL...
Epcoritamab is an investigational drug being studied for the treatment of patients with relapsed or refractory Large B Cell Lymphoma. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a clinical trial to assess its efficacy in this patient population.
Epcoritamab is a monoclonal antibody, indicated by its -mab suffix. As an antibody-based therapy, it is designed to bind to specific targets on cells. However, the specific molecular target of Epcoritamab has not been disclosed in the available information.
Epcoritamab is being developed by Incyte Corporation, a biopharmaceutical company traded on the stock exchange under the ticker symbol INCY. The company is conducting a Phase 2 clinical trial to evaluate the drug in patients with relapsed or refractory Large B Cell Lymphoma.
Epcoritamab is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is recruiting patients to evaluate the drug's efficacy in relapsed or refractory Large B Cell Lymphoma.
Epcoritamab is being studied in one active clinical trial with the identifier NCT07126236. This Phase 2 trial is titled 'Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma' and is recruiting participants in Spain. The trial is expected to enroll 80 patients aged 18 years and older.
Epcoritamab is also referred to as Eptoritamab in some contexts, as seen in the clinical trial title for NCT07126236. Both names appear to refer to the same investigational drug being developed by Incyte Corporation for the treatment of relapsed or refractory Large B Cell Lymphoma.